We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
- Authors
Toubi, E; Kessel, A; Rosner, I; Rozenbaum, M; Lorber, M; Paran, D; Sabo, E; Golan, T D
- Abstract
The benefit of combining quinacrine (Qn) with hydroxychloroquine (HCQ) in the treatment of systemic lupus erythematosus (SLE) was previously re-evaluated by us. In our current study we observed that, in 11 active SLE patients (SLEDAI score 5-12), the addition of Qn (100mg/day) to their existing ongoing therapeutic regimens resulted in a significant attenuation of their previously persistent anticardiolipin antibody (aCL) response. This was in comparison with a matched non-Qn treated control group composed of 14 randomly chosen aCL-positive SLE patients with a similar SLEDAI score 6-10. Prior to Qn treatment the therapeutic regimens of 12 months' duration, included in all cases HCQ (400mg/day), in many cases prednisone (P, 10-20mg/day) and in some additional cases immunosuppressive drugs. SLEDAI scores and aCL levels were monitored during the entire follow-up period which totaled 24 months in the study group and 15-18 months in the controls. Along with the beneficial effect of the added Qn on SLEDAI scores, aCL disappearance was documented in eight of 11 patients and remained negative during 8-12 months of follow-up (P =0.004), compared with such a change in only three of 14 non-Qn treated aCL-positive patients (P =0.18). We conclude that the added Qn treatment to former established therapeutic protocols may eliminate aCL response in SLE patients. Whether this agent's effect is permanent needs further elucidation.
- Subjects
QUINACRINE; SYSTEMIC lupus erythematosus; CARDIOLIPIN
- Publication
Lupus, 2003, Vol 12, Issue 4, p297
- ISSN
0961-2033
- Publication type
Article
- DOI
10.1191/0961203303lu319oa